Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sulindac. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 2/20 | 0.69 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.69 |
| ▸ | PPARG | P37231 | 14/20 | 0.78 |
| ▸ | RXRA | P19793 | 6/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.71 |
| ▸ | MAPT | P10636 | 3/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.71 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.71 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.71 |
| ▸ | GLA | P06280 | 1/20 | 0.71 |
| ▸ | TSHR | P16473 | 1/20 | 0.71 |
| ▸ | EDNRA | P25101 | 1/20 | 0.71 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.71 |
| ▸ | EGFR | P00533 | 1/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.69 |
| ▸ | DRD1 | P21728 | 1/20 | 0.69 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulindac SCHEMBL4203 | 1.00 | PPARG (0.78) | PPARGRXRACYP1A2MAPTMAPK1 | |
| Sulindac SCHEMBL30901384 | 1.00 | PPARG (0.78) | PPARGRXRACYP1A2MAPTMAPK1 | |
| Sulindac Sulfoxide SCHEMBL755984 | 1.00 | PPARG (0.78) | PPARGRXRACYP1A2MAPTMAPK1 | |
| Sulindac SCHEMBL31324645 | 1.00 | PPARG (0.78) | PPARGRXRACYP1A2MAPTMAPK1 | |
| Sulindac SCHEMBL4202 | 1.00 | PPARG (0.78) | PPARGRXRACYP1A2MAPTMAPK1 | |
| Sulindac SCHEMBL2029754 | 1.00 | PPARG (0.78) | PPARGRXRACYP1A2MAPTMAPK1 | |
| Sulindac SCHEMBL29360981 | 1.00 | PPARG (0.78) | PPARGRXRACYP1A2MAPTMAPK1 | |
| Sulindac SCHEMBL6903607 | 1.00 | PPARG (0.78) | PPARGRXRACYP1A2MAPTMAPK1 | |
| Sulindac Sulfoxide SCHEMBL11255653 | 1.00 | PPARG (0.78) | PPARGRXRACYP1A2MAPTMAPK1 | |
| Sulindac SCHEMBL15700834 | 1.00 | PPARG (0.78) | PPARGRXRACYP1A2MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102413-A1 | TREATING PAIN ASSOCIATED WITH CENTRAL SENSITIZATION | MEDICON PHARMACEUTICALS INC (US) | 2026-04-16 | — | — | US | claimed |
| WO-2025111078-A1 | ORAL ADMINISTRATION OF COMPOUNDS FOR TREATING PAIN | MEDICON PHARMACEUTICALS, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-20260102413-A1 | TREATING PAIN ASSOCIATED WITH CENTRAL SENSITIZATION | MEDICON PHARMACEUTICALS INC (US) | 2026-04-16 | — | — | US | disclosed |
| EP-4622638-A1 | TREATING PAIN ASSOCIATED WITH CENTRAL SENSITIZATION | Medicon Pharmaceuticals, Inc. (US) | 2025-10-01 | — | — | EP | disclosed |
| WO-2025111078-A1 | ORAL ADMINISTRATION OF COMPOUNDS FOR TREATING PAIN | MEDICON PHARMACEUTICALS, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| WO-2024112727-A1 | TREATING PAIN ASSOCIATED WITH CENTRAL SENSITIZATION | MEDICON PHARMACEUTICALS, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102413-A1 | TREATING PAIN ASSOCIATED WITH CENTRAL SENSITIZATION | P2RX4, P2RX3, P2RX2 | PTGS2 360/4885PTGS1 286/4885PPARG 4429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.